- Titre
- Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups
- Créateurs - sans rôle
- Anne-Laure Gagez - Université de Montpellier, Laboratory of Pathogens and Host Immunity - LPHIÉmilie Tuaillon - Université de Montpellier, Pathogenesis and Control of Chronic and Emerging Infections - PCCEIR Cezar - Hôpital Arnaud de VilleneuveCaroline Dartigeas - Centre Hospitalier Universitaire de ToursB Mahé - Centre d'Investigation Clinique de NantesRemi Letestu - Hôpital AvicenneHervé Maisonneuve - RocheValérie Gouilleux-Gruart - Université de ToursKarine Bolloré - Université de Montpellier, Pathogenesis and Control of Chronic and Emerging Infections - PCCEIE Ferrant - CHU Dijon BourgogneThérèse Aurran - Institut Paoli-CalmettesPatrick Feugier - Nutrition-Génétique et Exposition aux Risques EnvironnementauxS Leprêtre - Centre Henri BecquerelGuillaume Cartron - Université de Montpellier, Laboratory of Pathogens and Host Immunity - LPHI
- Détails de publication
- Blood Cancer Journal, Vol.6(1)
- Identifiants
- 99151853109311
- Unité académique
- Laboratory of Pathogens and Host Immunity - LPHI; Pathogenesis and Control of Chronic and Emerging Infections - PCCEI
- Langue
- English
- Type de ressource
- Journal article
- Champs locaux
- hal-01666834
Article de revue
Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups
Blood Cancer Journal, Vol.6(1)
22/01/2016
PMCID: PMC4742632
PMID: 26800078
Indicateurs
1 Consultations de la notice